A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 201–300 of 1,005
Zhu, G., Duffy, D. L., Eldridge, A., Grace, M., Mayne, C., O'Gorman, L., Aitken, J. F., Neale, M. C., Hayward, N. K., Green, A. C., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302494 · Cited by 238
“Another important risk factor for melanoma is germline mutation of the CDKN2A gene (MIM 155601, 600160), which encodes the cyclin-dependent kinase 4 (CDK4) inhibitor p16 ink4A (Kamb et al. 1994a).”
BackgroundWu, H., Wade, M., Krall, L., Grisham, J., Xiong, Y., & Van Dyke, T. (1996) · Genes & Development · doi:10.1101/gad.10.3.245 · Cited by 234
Phosphate-Regulated Inactivation of the Kinase PHO80-PHO85 by the CDK Inhibitor PHO81
Schneider, K. R., Smith, R. L., & O'Shea, E. K. (1994) · Science · doi:10.1126/science.7939631 · Cited by 235
Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
Sandig, V., Brand, K., Herwig, S., Lukas, J., Bartek, J., & Strauss, M. (1997) · Nature Medicine · doi:10.1038/nm0397-313 · Cited by 234
Lal, G., Liu, G., Schmocker, B., Kaurah, P., Özçelik, H., Narod, S. A., Redston, M. S., & Gallinger, S. (2000) · PubMed · Cited by 271
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
Kim, Y. B., Lee, K.-H., Sugita, K., Yoshida, M., & Horinouchi, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202564 · Cited by 232
“Chemical induction of p21WAF1/Cip1 or gelsolin may compensate for the functional loss of the tumor suppressor gene product p16MTS1/INK4A, another Cdk inhibitor (Kamb et al., 1994a,b; Nobori et al., 1994), or down-regulation of gelsolin in tumor cells.”
BackgroundTumor suppressor genes in normal and malignant hematopoiesis
Krug, U., Ganser, A., & Koeffler, H. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205322 · Cited by 231
“The gene for p15INK4B is localized in close proximity to the INK4A locus on chromosome 9p21 (Kamb et al., 1994).”
BackgroundDOCK4, a GTPase activator, is disrupted during tumorigenesis.
Yajnik, V., Paulding, C., Sordella, R., McClatchey, A. I., Saito, M., Wahrer, D. C. R., Reynolds, P., Bell, D. W., Lake, R., van den Heuvel, S., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00155-7 · Cited by 230
Molecular biology of gastric cancer*
ELRIFAI, W., & POWELL, S. (2002) · Seminars in Radiation Oncology · doi:10.1053/srao.2002.30815 · Cited by 231
Inactivation of p16 in Human Mammary Epithelial Cells by CpG Island Methylation
Foster, S. A., Wong, D. J., Barrett, M. T., & Galloway, D. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.1793 · Cited by 229
“1 STS marker is located within the p16 gene (29).”
BackgroundLee, R. J., Albanese, C., Stenger, R. J., Watanabe, G., Inghirami, G., Haines, G. K., Webster, M., Muller, W. J., Brugge, J. S., Davis, R. J., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7341 · Cited by 226
The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis
Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H., & DePinho, R. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207074 · Cited by 224
“Human genetic data suggest that both Ink4a/Arf products are important tumor-suppressor proteins (Hussussian et al., 1994; Kamb et al., 1994; FitzGerald et al., 1996; Randerson-Moor et al., 2001; Rizos et al., 2001; Hewitt et al., 2002).”
BackgroundTam, S. W., Shay, J. W., & Pagano, M. (1994) · PubMed · Cited by 241
Hypermethylation of tumor suppressor genes in cancer
Herman, J. G. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0138 · Cited by 218
Quelle, D. E., Cheng, M., Ashmun, R. A., & Sherr, C. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.669 · Cited by 220
Pathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 217
“CDKN2A locus is frequently deleted in melanoma of all primary subtypes [123-125].”
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
He, J., Allen, J. R., Collins, V. P., Allalunis‐Turner, M. J., Godbout, R., Day, R. S., & James, C. D. (1994) · PubMed · Cited by 238
André, E., Conquet, F., Steinmayr, M., Stratton, S. C., Porciatti, V., & Becker-André, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.14.3867 · Cited by 214
Risk of cutaneous melanoma associated with a family history of the disease
Ford, D., Bliss, J. M., Swerdlow, A. J., Armstrong, B. K., Franceschi, S., Green, A., Holly, E. A., Mack, T., Mackie, R. M., Østerlind, A., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620403 · Cited by 216
Park, M.-T., & Lee, S.-J. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.060 · Cited by 200
“, 1993), has been mapped to chromosome 9p21 (Kamb et al., 1994).”
BackgroundMutagenic and epigenetic effects of DNA methylation
Gonzalgo, M. L., & Jones, P. A. (1997) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(96)00047-6 · Cited by 213
Eugenol Causes Melanoma Growth Suppression through Inhibition of E2F1 Transcriptional Activity
Ghosh, R., Nadiminty, N., Fitzpatrick, J. E., Alworth, W. L., Slaga, T. J., & Kumar, A. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411429200 · Cited by 210
Human tumor antigens recognized by T cells
Robbins, P. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80078-1 · Cited by 210
Straume, O., Sviland, L., & Akslen, L. A. (2000) · PubMed · Cited by 238
Molecular biology of lung cancer: Clinical implications
Fong, K. M., & Minna, J. D. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00062-5 · Cited by 209
Role of telomeric sequences in murine radiation-induced myeloid leukaemia
Meijne, E. I. M., Silver, A. R., Bouffler, S. D., Morris, D. J., van Kampen, E. W., Spanjer, S., Huiskamp, R., & Cox, R. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199608)16:4<238::aid-gcc3>3.0.co;2-z · Cited by 9
Sulong, S., Moorman, A. V., Irving, J. A. E., Strefford, J. C., Konn, Z. J., Case, M. C., Minto, L., Barber, K. E., Parker, H., Wright, S. L., et al. (2009) · Blood · doi:10.1182/blood-2008-07-166801 · Cited by 207
Genetic progression and clonal relationship of recurrent premalignant head and neck lesions.
Califano, J. A., Westra, W. H., Meininger, G. R., Corio, R., Koch, W. M., & Sidransky, D. (2000) · PubMed · Cited by 242
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Aprelikova, O., Xiong, Y., & Liu, E. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.31.18195 · Cited by 203
Abrogation of p27 by cDNA Antisense Suppresses Quiescence (G0 State) in Fibroblasts
Rivard, N., L'Allemain, G., Bartek, J., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18337 · Cited by 203
Epigenetic regulation of the INK4b-ARF-INK4a locus: In sickness and in health
Popov, N., & Gil, J. (2010) · Epigenetics · doi:10.4161/epi.5.8.12996 · Cited by 202
p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma
Matsuda, Y., Ichida, T., Matsuzawa, J., Sugimura, K., & Asakura, H. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70137-x · Cited by 202
Bashyam, M. D., Bair, R., Kim, Y. H., Wang, P., Hernandez-Boussard, T., Karikari, C. A., Tibshirani, R., Maitra, A., & Pollack, J. R. (2005) · Neoplasia · doi:10.1593/neo.04586 · Cited by 201
CDKN2A Variants in a Population-Based Sample of Queensland Families With Melanoma
Aitken, J., Welch, J., Duffy, D., Milligan, A., Green, A., Martin, N., & Hayward, N. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.446 · Cited by 200
Guo, Y., Sklar, G. N., Borkowski, A., & Kyprianou, N. (1997) · PubMed · Cited by 200
FitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8541 · Cited by 200
A Molecular Genetic Model of Astrocytoma Histopathology
Louis, D. N. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb01062.x · Cited by 199
Magdinier, F., & Wolffe, A. P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101617298 · Cited by 197
Sill, H., Goldman, J., & Cross, N. (1995) · Blood · doi:10.1182/blood.v85.8.2013.bloodjournal8582013 · Cited by 197
Genetic and Epigenetic Changes in Human Epithelial Cells Immortalized by Telomerase
Farwell, D. G., Shera, K. A., Koop, J. I., Bonnet, G. A., Matthews, C. P., Reuther, G. W., Coltrera, M. D., McDougall, J. K., & Klingelhutz, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65025-0 · Cited by 196
Sandhu, C., Garbe, J., Bhattacharya, N., Daksis, J., Pan, C.-H., Yaswen, P., Koh, J., Slingerland, J. M., & Stampfer, M. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2458 · Cited by 194
“The first of the INK4 family genes to be cloned, the p16 (60) gene, or multiple-tumor suppressor 1 (28), is mutated in many human tumors and cell lines.”
BackgroundHuman mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
Teng, D. H. ‐., Perry, W. L., Hogan, J. K., Baumgard, M., Bell, R. N., Berry, S., Davis, T., Frank, D., Frye, C., Hattier, T., et al. (1997) · PubMed · Cited by 193
Acs, G., Zhang, P. J., McGrath, C. M., Acs, P., McBroom, J., Mohyeldin, A., Liu, S., Lu, H., & Verma, A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64314-3 · Cited by 193
Prognostic factors in uveal melanoma
Singh, A. D., Shields, C. L., & Shields, J. A. (2001) · Melanoma Research · doi:10.1097/00008390-200106000-00007 · Cited by 190
Hruban, R. H., Petersen, G. M., Ha, P. K., & Kern, S. E. (1998) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30282-5 · Cited by 191
Lee, M.-H., & Yang, H.-Y. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000826 · Cited by 192
Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia
Okuda, T., Shurtleff, S., Valentine, M., Raimondi, S., Head, D., Behm, F., Curcio- Brint, A., Liu, Q., Pui, C., & Sherr, C. (1995) · Blood · doi:10.1182/blood.v85.9.2321.bloodjournal8592321 · Cited by 192
Wong, I. H., Lo, Y. M., Yeo, W., Lau, W. Y., & Johnson, P. J. (2000) · PubMed · Cited by 190
The E6 and E7 Proteins of the Cutaneous Human Papillomavirus Type 38 Display Transforming Properties
Caldeira, S., Zehbe, I., Accardi, R., Malanchi, I., Dong, W., Giarrè, M., de Villiers, E.-M., Filotico, R., Boukamp, P., & Tommasino, M. (2003) · Journal of Virology · doi:10.1128/jvi.77.3.2195-2206.2003 · Cited by 190
“Loss of its expression favors tumor development in mice (44) and is a common event in human cancers (12, 25 ).”
BackgroundHocker, T. L., Singh, M. K., & Tsao, H. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.226 · Cited by 189
“Subsequent deletional analyses localized regions of loss-of-heterozygosity on chromosome 9p (Fountain et al., 1992) with mutational analyses revealing deleterious changes in the CDKN2A gene in a high percentage of cancer lines, including melanoma (Kamb et al., 1994).”
BackgroundArendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 188
Prognostic parameters in uveal melanoma: a review
Mooy, C. M., & De Jong, P. T. V. M. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80024-5 · Cited by 188
(1996) · Lung Cancer · doi:10.1016/0169-5002(96)87762-2 · Cited by 188
Frequent Hypermethylation of p16 and p15 Genes in Multiple Myeloma
Ng, M. H. L., Chung, Y. F., Lo, K. W., Wickham, N. W. R., Lee, J. C. K., & Huang, D. P. (1997) · Blood · doi:10.1182/blood.v89.7.2500 · Cited by 187
Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
Klump, B., Hsieh, C.-J., Holzmann, K., Gregor, M., & Porschen, R. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70016-2 · Cited by 186
Human Adenovirus Vectors for Gene Transfer into Mammalian Cells
Hitt, M. M., Addison, C. L., & Graham, F. L. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60140-4 · Cited by 186
Mandatory second opinion surgical pathology at a large referral hospital
Kronz, J. D., Westra, W. H., & Epstein, J. I. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11<2426::aid-cncr34>3.0.co;2-3 · Cited by 283
Lu, S., Liu, M., Epner, D. E., Tsai, M., & Tsai, M. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.376 · Cited by 185
A tiger behind many doors: multiple genetic pathways to malignant glioma
Louis, D. N., & Gusella, J. F. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89125-8 · Cited by 185
Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines
Gayet, J., Zhou, X.-P., Duval, A., Rolland, S., Hoang, J.-M., Cottu, P., & Hamelin, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204611 · Cited by 186
“It has to be noted that in any of the 22 cell lines, we observed an homozygous p16 deletion as it has been reported for primary tumors of other organs (Kamb et al., 1994).”
BackgroundElenitoba-Johnson, K. S. J., Gascoyne, R. D., Lim, M. S., Chhanabai, M., Jaffe, E. S., & Raffeld, M. (1998) · Blood · doi:10.1182/blood.v91.12.4677 · Cited by 179
Methylation Silencing and Mutations of the p14ARF and p16INK4a Genes in Colon Cancer
Burri, N., Shaw, P., Bouzourene, H., Sordat, I., Sordat, B., Gillet, M., Schorderet, D., Bosman, F. T., & Chaubert, P. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780230 · Cited by 181
“In human tumors, the p16INK4a gene is frequently inactivated by homozygous deletions, point mutations (Cairns et al, 1994; Kamb et al, 1994; Okamoto et al, 1994; Spruck et al, 1994), or de novo methylation of its promoter region (Gonzales-Zulueta”
BackgroundBian, Y., Osterheld, M., Fontolliet, C., Bosman, F. T., & Benhattar, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32370 · Cited by 182
Cutaneous Photobiology. The Melanocyte vs. the Sun: Who Will Win the Final Round?
Kadekaro, A. L., Kavanagh, R. J., Wakamatsu, K., Ito, S., Pipitone, M. A., & Abdel‐Malek, Z. A. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00088.x · Cited by 180
Identification, localization and characterization of the human γ-synuclein gene
Lavedan, C., Leroy, E., Dehejia, A., Buchholtz, S., Dutra, A., Nussbaum, R. L., & Polymeropoulos, M. H. (1998) · Human Genetics · doi:10.1007/s004390050792 · Cited by 179
“1995), and MTS1 (Kamb et al. 1994); amplification and/or overexpression of proto-oncogenes such as HER-2/neu”
High frequency of p16INK4A gene alterations in hepatocellular carcinoma
Liew, C. T., Li, H.-M., Lo, K.-W., Leow, C. K., Chan, J. Y., Hin, L. Y., Lau, W. Y., Lai, P. B. S., Lim, B. K., Huang, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202359 · Cited by 180
“The p16 gene is believed to encode a negative regulatory protein which prevents the cell cycle progression from G1 to S phase by inhibiting the catalytic activity of the CDK4 or CDK6/cyclin D complex and subsequently Rb protein phosphorylation (Serrano et al., 1993; Kamb et al., 1994).”
BackgroundHazelbag, S., Kenter, G., Gorter, A., Dreef, E., Koopman, L., Violette, S., Weinreb, P., & Fleuren, G. (2007) · The Journal of Pathology · doi:10.1002/path.2168 · Cited by 178
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma
Cooke, S. L., Ng, C. K. Y., Melnyk, N., Garcia, M. J., Hardcastle, T., Temple, J., Langdon, S., Huntsman, D., & Brenton, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.245 · Cited by 178
“However, three of these included tumour suppressor genes p16INK4a/ARF (Kamb et al., 1994), WWOX (Paige et al., 2001), and NF2 (merlin) (Curto and McClatchey, 2008; Trofatter et al., 1993), two affected RAB32 (Schulmann et al., 2005) and GNG7 (Shibata et Oncogene.”
BackgroundControl of p53 ubiquitination and nuclear export by MDM2 and ARF.
Zhang, Y., & Xiong, Y. (2001) · PubMed · Cited by 214
Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins
Gong, Y., Zack, T. I., Morris, L. G. T., Lin, K., Hukkelhoven, E., Raheja, R., Tan, I.-L., Turcan, S., Veeriah, S., Meng, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2981 · Cited by 177
Adenovirus and Adeno-Associated Virus Vectors
Lai, C. M., Lai, Y. K. Y., & Rakoczy, P. E. (2002) · DNA and Cell Biology · doi:10.1089/104454902762053855 · Cited by 175
Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins
Beijersbergen, R. L., & Bernards, R. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(96)00002-9 · Cited by 176
Lu, S., Tsai, S. Y., & Tsai, M. (1997) · PubMed · Cited by 191
Kaneko, Y., Yoshida, K., Handa, M., Toyoda, Y., Nishihira, H., Tanaka, Y., Sasaki, Y., Ishida, S., Higashino, F., & Fujinaga, K. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199602)15:2<115::aid-gcc6>3.0.co;2-6 · Cited by 239
Melanocortin-1 Receptor Variant R151C Modifies Melanoma Risk in Dutch Families with Melanoma
van der Velden, P. A., Sandkuijl, L. A., Bergman, W., Pavel, S., van Mourik, L., Frants, R. R., & Gruis, N. A. (2001) · The American Journal of Human Genetics · doi:10.1086/323411 · Cited by 173
Loukopoulos, P., Kanetaka, K., Takamura, M., Shibata, T., Sakamoto, M., & Hirohashi, S. (2004) · Pancreas · doi:10.1097/00006676-200410000-00004 · Cited by 172
Haanen, C., & Vermes, I. (1995) · Mediators of Inflammation · doi:10.1155/s0962935195000020 · Cited by 172
The genomic landscape of cutaneous melanoma
Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12459 · Cited by 172
Kriajevska, M. V., Cardenas, M. N., Grigorian, M. S., Ambartsumian, N. S., Georgiev, G. P., & Lukanidin, E. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32072-0 · Cited by 171
Cyclins and Cyclin-Dependent Kinases: Theme and Variations
(1995) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60254-7 · Cited by 172
Senescence Regulation by the p53 Protein Family
Qian, Y., & Chen, X. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_3 · Cited by 171
“p19ARF (p14ARF in human) is encoded from an alternative reading frame within the INK4a/ARF locus which also encodes p16 (79, 80).”
BackgroundVersteege, I., Medjkane, S., Rouillard, D., & Delattre, O. (2002) · Oncogene · doi:10.1038/sj.onc.1205841 · Cited by 171
“U2OS osteosarcoma cells lack the p16INK4A inhibitor of the cyclin D1/CDK4 complex and therefore express an hyperphosphorylated pRb protein (Craig et al., 1998; Kamb et al., 1994).”
BackgroundEvaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia
Tringler, B., Gup, C. J., Singh, M., Groshong, S., Shroyer, A. L., Heinz, D. E., & Shroyer, K. R. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.02.012 · Cited by 170
Stewart, Z. A., Leach, S. D., & Pietenpol, J. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.205 · Cited by 168
“There are four known INK4 family members, p16 (48), p15 (13, 24), p19 (21), and p18 (21), and three known Cip/Kip family members, p21 (10, 60), p27 (44, 45, 53), and p57 (28, 31).”
Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization
Arendt, T. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00516-9 · Cited by 169
Pérez-Simón, J. A., Garcı́a-Sanz, R., Tabernero, M. D., Almeida, J., González, M., Fernández-Calvo, J., Moro, M. J., Hernández, J. M., Miguel, J. F. S., & Orfão, A. (1998) · Blood · doi:10.1182/blood.v91.9.3366 · Cited by 169
Taniguchi, K., Kohsaka, H., Inoue, N., Terada, Y., Ito, H., Hirokawa, K., & Miyasaka, N. (1999) · Nature Medicine · doi:10.1038/10480 · Cited by 168
“Although mutations and deletions of the p16 INK4a gene occur frequently in human malignancie”
BackgroundKourea, H. P., Orlow, I., Scheithauer, B. W., Cordon-Cardo, C., & Woodruff, J. M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65504-6 · Cited by 170
Zhang, Z. T., Pak, J., Shapiro, E., Sun, T., & Wu, X. (1999) · PubMed · Cited by 189
Phenotype and Genotype of Advanced Premalignant Head and Neck Lesions After Chemopreventive Therapy
Mao, L., Papadimitrakopoulou, V., Shin, D. M., Fan, Y., Zhou, X., Lee, J. S., Hong, W. K., El-Naggar, A. K., Shin, H. C., Clayman, G., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1545 · Cited by 168
Rane, S. G., Cosenza, S. C., Mettus, R. V., & Reddy, E. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.2.644-656.2002 · Cited by 167
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma
Sandberg, A. A. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.08.005 · Cited by 166
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone, G. G. M., Teofili, L., Voso, M. T., & Lübbert, M. (2002) · PubMed · Cited by 200
Somatic alterations in the human cancer genome
Weir, B., Zhao, X., & Meyerson, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.004 · Cited by 166
p16 INK4A Participates in a G 1 Arrest Checkpoint in Response to DNA Damage
Shapiro, G. I., Edwards, C. D., Ewen, M. E., & Rollins, B. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.378 · Cited by 165
“First, its gene maps to 9p21, a chromosomal locus deranged in many human cancers ( 15 ).”
BackgroundThe role of RB in cell cycle control
Hatakeyama, M., & Weinberg, R. A. (1995) · Progress in Cell Cycle Research · doi:10.1007/978-1-4615-1809-9_2 · Cited by 164
Byeon, I.-J. L., Li, J., Ericson, K., Selby, T. L., Tevelev, A., Kim, H.-J., O'Maille, P., & Tsai, M.-D. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80042-8 · Cited by 163
Invasive melanoma in Cdk4-targeted mice
Sotillo, R., García, J. F., Ortega, S., Martín, J., Dubus, P., Barbacid, M., & Malumbres, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241338598 · Cited by 164
Murthy, S. S., & Testa, J. R. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199908)180:2<150::aid-jcp2>3.0.co;2-h · Cited by 175
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.